JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Antiseizure medications and their differing effects on cardiovascular risk

  • 0Department of Neurology, Temple University, Philadelphia, PA, United States.
Epilepsy & Behavior Reports +

|

February 26, 2025

|

February 26, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Enzyme-inducing and non-inducing antiseizure medications impact cardiovascular risk markers differently. Understanding these effects is crucial for managing epilepsy patients and their long-term health outcomes.

Area Of Science

  • Pharmacology
  • Cardiology
  • Neurology

Background

  • Antiseizure medications (ASMs) are essential for epilepsy management.
  • ASMs can be categorized as enzyme-inducing or non-inducing, with potential differential effects on cardiovascular health.
  • Cardiovascular risk in epilepsy patients is a growing concern.

Purpose Of The Study

  • To review the distinct cardiovascular effects of enzyme-inducing and non-inducing ASMs.
  • To explore the implications of these effects on epilepsy patient management strategies.
  • To discuss the clinical relevance of ASM-induced cardiovascular changes for practicing clinicians.

Main Methods

  • Literature review of studies examining ASM effects on cardiovascular risk markers.
  • Analysis of data on traditional lipid profiles (LDL, HDL, triglycerides) and other vascular risk indicators (CRP, non-HDL, homocysteine).
  • Consideration of indirect effects on neuroendocrine function and metabolic syndrome.

Main Results

  • Both enzyme induction and inhibition by ASMs alter traditional cardiovascular risk markers.
  • ASMs affect other vascular risk markers like C-reactive protein and homocysteine, with potential age-related differences.
  • Long-term cardiovascular risks associated with specific ASMs like enzyme-inducing agents and valproic acid are identifiable.
  • Effects on cardiac rhythm and autonomic control are also noted.

Conclusions

  • The cardiovascular risk profile in epilepsy patients is complex and influenced by ASM type.
  • Individualized management strategies are necessary to mitigate ASM-related cardiovascular risks.
  • Clinicians must consider cardiac rhythm and autonomic control when prescribing ASMs.

Keywords:

Related Concept Videos

Antiepileptic Drugs: Calcium Channel Blockers 01:17

291

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

Antiepileptic Drugs: Sodium Channel Blockers 01:08

347

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers 01:22

1.2K

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers 01:20

756

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein 01:20

209

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers 01:24

700

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...